Status:
COMPLETED
Endometriosis-Angiopoietin-like Protein-4
Lead Sponsor:
Ankara City Hospital Bilkent
Conditions:
Endometriosis
Angiopoietin-like Protein-4
Eligibility:
FEMALE
18-44 years
Brief Summary
Endometriosis is a chronic inflammatory disease associated with pelvic pain, dyspareunia, and impaired ovarian reserve. Cancer antigen-125 (CA-125) is widely studied but limited by low specificity, wh...
Eligibility Criteria
Inclusion
- Diagnosis of endometriosis for study group who underwent laparoscopic endometriosis surgery
- Healthy women for control group
Exclusion
- Cardiovascular diseases including hypertension
- Type 1 or type 2 diabetes mellitus
- Morbid obesity
- Primary adrenal insufficiency
- Uterine fibroids
- Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease
- Hepatic dysfunctions
- Renal insufficiency
- Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9
- Neurologic diseases
- Psychiatric disorders
- Autoimmune diseases or syndromes including Addison's disease, autoimmune syndromes, scleroderma, Sjogren's syndrome, myasthenia gravis, inflammatory bowel diseases, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus and familial Mediterranean fever
- History of any malignancy
- History of exposure to chemotherapeutic agents or radiotherapy
Key Trial Info
Start Date :
June 5 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 2 2025
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT07164196
Start Date
June 5 2025
End Date
September 2 2025
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ankara Bilkent City Hospital
Ankara, Not Valid, Turkey (Türkiye), 06100